Our Life Sciences Transactions Practice assists clients in structuring, negotiating and implementing merger & acquisition, joint venture, strategic alliance, corporate partnering, licensing, financing and outsourcing transactions to help them achieve their business goals. Our ability to also provide the life sciences regulatory, scientific and litigation assessment components necessary to a transaction (including intellectual property, FDA/healthcare regulatory, product liability, outsourcing, tax, antitrust, labor and employment, employee benefits and real estate), uniquely positions us to successfully complete transactions in a coordinated and efficient manner. Representative transactions include:
- Closure Medical in its $421 million acquisition by Johnson & Johnson
- Biovail in its product divestiture, strategic collaboration and research and development alliance with Kos Pharmaceuticals in the area of cardiovascular disease
- WR Hambrecht + Co. LLC as underwriter for the IPOs of HemoSense Inc. and CryoCor Inc.
- Bristol-Myers Squibb in the outsourcing of certain administrative and clinical functions
- One Equity Partners in its acquisition from Bristol-Myers Squibb of Oncology Therapeutics Network
- Shire in its up to $500 million collaboration with New River Pharmaceuticals for the development and commercialization of a late-stage ADHD compound
- JPMorgan as underwriter for the follow-on offering by Bioenvision
- Wyeth in the outsourcing of certain clinical and regulatory functions to Accenture
- Schering-Plough in its acquisition of Bayer AG’s primary care pharmaceutical product business in the United States and related strategic alliances on oncology products and on Zetia® in Japan
- Cancervax in its $290 million collaboration with Serono for the development and commercialization of its cancer therapy, Canvaxin®
- Barrier Therapeutics in its IPO and follow-on offerings underwritten by Morgan Stanley, and previous spin-off from, and related licensing arrangements with, Johnson & Johnson, and venture capital financing led by TL Ventures
- Sanofi-Aventis in the restructuring of its Actonel® collaboration with Procter & Gamble
- Esperion in its acquisition by Pfizer for $1.3 billion
- Adolor in its co-promotion agreement with GlaxoSmithKline for Arixtra®
- JPMorgan as underwriter for the IPO of TolerRx
- Viasys Holdings in its acquisition of the medical device division of Oxford Instruments plc
- Takeda in its $210 million collaboration with Sucampo for the development and commercialization of lubiprostone for the treatment of IBS
- Aventis in the divestiture of Campto® to Pfizer
- Pharmasset in its $300 million collaboration with Roche to develop and commercialize nucleoside polymerase inhibitors for the treatment of chronic hepatitis C virus infections
- 3-Dimensional Pharmaceuticals in its acquisition by Johnson & Johnson
- Cell Pathways in its stock-for-stock acquisition by OSI Pharmaceuticals
- Aventis in its up to $485 million collaboration with Regeneron to develop and commercialize VEGF-Trap products, and related equity investment
- Enzon in its acquisition of Abelcet® product rights and related manufacturing facility and other assets from Elan for $370 million
- JPMorgan in the $200 million follow-on offering by Emisphere Technologies
- Cephalon in its $444 million stock-for-stock acquisition of Anesta
- Arena Pharmaceuticals in its IPO and follow-on offerings
- Pharmacia in the divestiture of its late stage compound to Nastech in connection with its then proposed merger with Pfizer
- Principia in its stock-for-stock acquisition by Human Genome Sciences
- Pharmacia in the restructuring of its Lorex joint venture with Sanofi for the marketing of Ambien®
- Eos Biotechnology in its collaboration agreements with ICOS, Seattle Genetics and Avanir